Search Within

Alison Michele Schram

  1. "GSK Faculty"
Formats
  1. Journal Article (26)
  2. Meeting Abstract (24)
  3. Editorial (1)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Department of Medicine (53)
  2. Early Drug Development Service (53)
  3. GSK Faculty (53)
  4. Gynecologic Medicine Service (53)
  5. Solid Tumor Oncology Division (53)
  6. Human Oncology and Pathogenesis Program (45)

More Groups

People
  1. David Hyman (33)
  2. Alexander Drilon (26)
  3. Michael Berger (23)
  4. Barry Taylor (16)
  5. Marc Ladanyi (16)
  6. Ryma Benayed (14)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (3)
  4. 2022 (6)
  5. 2021 (6)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Cancer Research (9)
  3. Cancer Discovery (6)
  4. Clinical Cancer Research (5)
  5. Annals of Oncology (3)
  6. Blood (2)

More Publications

Publishers
  1. American Association for Cancer Research (21)
  2. American Society of Clinical Oncology (12)
  3. Nature Publishing Group (8)
  4. Oxford University Press (3)
  5. American Society of Hematology (2)
  6. Cell Press (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
    Meeting Abstract

    Liu, B.; Ross, D. S.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Meeting Abstract

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arena, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis
    Meeting Abstract

    Bolton, K. L.; Moukarzel, L. A.; Ptashkin, R.; Gao, T.; Patel, M.; Caltabellotta, N.; Braunstein, L. Z.; Aghajanian, C.; Hyman, D. M.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Landscape and outcome of TRK fusion-positive cancers
    Meeting Abstract

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Batist, G.; Meric-Bernstam, F.; Kabos, P.; Spanggaard, I.; Lluch, A.; Schram, A.; Varga, A.; Wong, A.; Ambrose, H.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
    Journal Article

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Toward a more precise future for oncology
    Editorial

    Murciano-Goroff, Y. R.; Taylor, B. S.; Hyman, D. M.; Schram, A. M.
    Cancer Cell (2020)

    Fulltext@MSK | Save
  • Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer
    Journal Article

    Smyth, L. M.; Piha-Paul, S. A.; Won, H. H.; Schram, A. M.; Saura, C.; Loi, S.; Lu, J.; Shapiro, G. I.; Juric, D.; Mayer, I. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
    Meeting Abstract

    Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; more...
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save